Latest market price
16.75
-0.83-4.72%
OverviewShort InterestFilings
BBNXQT62Beta Bionics, Inc.·NASDAQ
16.75-4.72%
TA
Loading chart...
Signal & projected range
Insider selling clusterHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
INMD-2.15%$13.22VREX-0.05%$18.43AHCO-2.02%$5.81CTKB-2.70%$6.13KIDS-2.06%$30.87PACB-10.00%$2.61BVS-10.36%$13.33AVR-1.71%$6.31
Snapshot
Index—P/E—EPS (ttm)-1.87Insider Own12.50%Shs Outstand44.99MPerf Week-12.58%
Market Cap753.58MForward P/E—EPS next Y-2.14Insider Trans-4.06%Shs Float20.04MPerf Month-11.23%
Enterprise Value518.58MPEG—EPS next Q—Short Float34.52%Perf Quarter25.47%
Income-82.00MP/S5.89EPS this Y—Short Ratio5.36Perf Half Y62.78%
Sales128.00MP/B1.88EPS next Y—ROA-18.73%Short Interest6.92MPerf YTD-45.03%
Book/sh8.91P/C3.14EPS next 5Y—ROE-27.33%52W High32.71 -48.79%Perf Year-37.48%
Cash/sh5.33P/FCF—EPS past 3/5Y—ROIC-22.45%52W Low8.80 90.34%Perf 3Y—
Dividend Est.—EV/EBITDA—Sales past 3/5Y—Gross Margin58.63%Volatility10.13% 6.43%Perf 5Y—
Dividend TTM—EV/Sales4.05EPS Y/Y TTM—Oper. Margin-72.75%ATR (14)1.46Perf 10Y—
Dividend Ex-Date—Quick Ratio8.22Sales Y/Y TTM45.45%Profit Margin-65.31%RSI (14)41.51Recom2.33
Dividend Gr. 3/5Y—Current Ratio8.92EPS Q/Q-57.58%SMA20-7.55%Beta1.24Target Price24.67
Payout0.00%Debt/Eq0.01Sales Q/Q33.33%SMA50-12.33%Rel Volume0.85Prev Close17.58
Employees422LT Debt/Eq0.01EarningsMar 30SMA20013.04%Avg Volume1.26MPrice16.75
IPO DateJan 30, 2025Option/ShortYes / YesEPS/Sales Surpr.0.64% 2.26%Net Debt/EBITDA—Volume1,072,454Change-4.72%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-28-26ReiteratedPiper SandlerOverweight$32 → $24
Oct-12-26ReiteratedJefferies$30
Oct-06-26InitiatedBarclaysOverweight$30
Sep-23-26InitiatedWells FargoOverweight$28
Sep-15-26ReiteratedRobert W. Baird$14 → $16
Sep-15-26ReiteratedUBS$22 → $25
Sep-15-26ReiteratedTruist SecuritiesBuy$22 → $23
Sep-14-26ReiteratedLeerink PartnersOutperform$27
Jul-28-26ResumedUBSBuy$24 → $22
Jul-15-26ReiteratedGoldman SachsBuy$17 → $19
Latest News· Times ET
Nov-01-26
Nov-01-2601:00PM
Bronstein, Gewirtz & Grossman LLC Urges Beta Bionics, Inc. Investors to Act: Class Action Filed Alleging Investor Harmglobenewswire.com
09:49AM
BBNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Beta Bionics (BBNX) Investors of Securities Class Action Lawsuit Deadline on November 3, 2026newsfilecorp.com
Oct-30-26
Oct-30-2605:08PM
BBNX FINAL DEADLINE: ROSEN, REGARDED INVESTOR RIGHTS COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNXnewsfilecorp.com
01:54PM
BBNX SHAREHOLDER NOTICE: Beta Bionics Investors with Substantial Losses Have Opportunity to Lead Securities Class Actionprnewswire.com
01:00PM
Kaplan Fox Alerts Investors of Beta Bionics, Inc. (NASDAQ: BBNX) to an Upcoming Deadline of November 3, 2026 in the Securities Class Actionglobenewswire.com
09:49AM
BBNX CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Beta Bionics (BBNX) Investors of Securities Class Action Lawsuit Deadline on November 3, 2026newsfilecorp.com
09:21AM
CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Beta Bionics, Inc. (BBNX) Investors to Inquire About a Securities Fraud Class Action by November 3, 2026newsfilecorp.com
06:18AM
BBNX Lawsuit Reminder: Beta Bionics Hit with Securities Fraud Class Action Over Medical Device Safety Issues – BFA Law Reminds Investors of the November 3 Deadlineglobenewswire.com
04:30AM
Kaplan Fox Encourages Beta Bionics, Inc. (BBNX) Investors With Significant Losses to Take Action Before the November 3, 2026 Lead Plaintiff Deadlinenewsfilecorp.com
Oct-29-26
Oct-29-2609:05PM
BBNX DEADLINE NOTICE: ROSEN, A LONGSTANDING FIRM, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNXglobenewswire.com
07:04PM
BBNX Deadline: BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuitprnewswire.com
06:18PM
Beta Bionics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Beta Bionics, Inc. - BBNXglobenewswire.com
03:41PM
Beta Bionics Investors Should Contact Block & Leviton Before November 3 to Lead Securities Fraud Class Actionnewsfilecorp.com
10:09AM
BBNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Beta Bionics, Inc. Securities Lawsuit - Contact SueWallStprnewswire.com
10:01AM
BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuitglobenewswire.com
Company

Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
Total Revenue1281006512—
Cost of Goods Sold Incl. D&A5245296—
Gross Profit7456366—
Selling, General and Administrative Excl. Other124925524—
Research and Development42352618—
Other Operating Expense
1000—
Operating Income-93-72-45-36—
Interest Expense
0000—
Unusual Expense
—————
Non-Operating Income (Expense)9-2-10-8—
Net Income Before Taxes-82-73-55-44—
Income Taxes
0000—
Consolidated Net Income-82-73-55-44—
Net Income From Continuing Operations-82-73-55-44—
Net Income-82-73-55-44—
EPS (Recurring)-1.87-1.81-1.28-1.03—
EPS (Basic, Before Extraordinaries)-1.87-1.81-1.28-1.03—
EPS (Diluted)-1.87-1.81-1.28-1.03—
EBITDA-83-70-52-42—
Other After Tax Adjustments
—————
Stock Option Compensation Expense
—————
Price To Earnings Ratio
—————
Price To Sales Ratio6.1512.49———
Gross Margin57.8156.0055.3850.00—
Operating Margin-72.66-72.00-69.23-300.00—
Net Margin-64.06-73.00-84.62-366.67—
Shares Outstanding47414343—
Market Capitalization7871,249———
Operating Lease Expense
—————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$35.46$27.94$20.42$12.91$5.39● Close Price0.00M0.75M1.51M2.26M3.01MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Mensinger MikeChief Product OfficerOct 27 '26Sale22.002,65058,300174,740Oct 29
Hopman MarkChief Commercial OfficerOct 26 '26Sale20.0082116,42054,513Oct 28
Hopman MarkChief Commercial OfficerOct 14 '26Sale17.3577513,44655,334Oct 16
Hopman MarkChief Commercial OfficerOct 01 '26Sale18.963707,01556,109Oct 05
Jones ChristyDirectorSep 22 '26Sale23.006,430147,89019,564Sep 23
Hopman MarkChief Commercial OfficerSep 09 '26Sale18.4672,8641,345,27387,157Sep 18
Hopman MarkChief Commercial OfficerSep 16 '26Sale20.1330,779619,64056,479Sep 17
Mensinger MikeChief Product OfficerSep 16 '26Sale22.002,65058,300177,390Sep 17
Hopman MarkChief Commercial OfficerSep 14 '26Sale15.5277512,02886,382Sep 15
Saint SeanPresident & CEOSep 03 '26Sale20.085,641113,259398,429Sep 04
Hopman MarkChief Commercial OfficerSep 02 '26Sale19.115,327101,815124,027Sep 03
Russell Steven JonChief Medical OfficerSep 02 '26Sale19.114,22180,676169,628Sep 03
Mensinger MikeChief Product OfficerSep 02 '26Sale19.114,37583,620180,040Sep 03
Feider StephenChief Financial OfficerSep 02 '26Sale19.116,675127,580159,378Sep 03
Saint SeanPresident & CEOSep 02 '26Sale19.1116,867322,381404,070Sep 03
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.